The goal of the Arrestee Drug Abuse Monitoring (ADAM) Program is to determine the extent and correlates of illicit drug use in the population of booked arrestees in local areas. Data were collected in 2003 up to four separate times (quarterly) during the year in 39 metropolitan areas in the United States. The ADAM program adopted a new instrument in 2000 in adult booking facilities for male (Part 1) and female (Part 2) arrestees. The ADAM program in 2003 also continued the use of probability-based sampling for male arrestees in adult facilities, which was initiated in 2000. Therefore, the male adult sample includes weights, generated through post-sampling stratification of the data. For the adult male and female files, variables fell into one of eight categories: (1) demographic data on each arrestee, (2) ADAM facesheet (records-based) data, (3) data on disposition of the case, including accession to a verbal consent script, (4) calendar of admissions to substance abuse and mental health treatment programs, (5) data on alcohol and drug use, abuse, and dependence, (6) drug acquisition data covering the five most commonly used illicit drugs, (7) urine test results, and (8) for males, weights.

ADAM is organized as a half day Challenge, a Satellite Event of the ISBI 2020 conference in Iowa City, Iowa, USA.

The ADAM challenge focuses on the investigation and development of algorithms associated with the diagnosis of Age-related Macular degeneration (AMD) and segmentation of lesions in fundus photos from AMD patients. The goal of the challenge is to evaluate and compare automated algorithms for the detection of AMD on a common dataset of retinal fundus images. We invite the medical image analysis community to participate by developing and testing existing and novel automated fundus classification and segmentation methods.

Instructions: ADAM: Automatic Detection challenge on Age-related Macular degeneration

Link: https://amd.grand-challenge.org

Age-related macular degeneration, abbreviated as AMD, is a degenerative disorder in the macular region. It mainly occurs in people older than 45 years old and its incidence rate is even higher than diabetic retinopathy in the elderly.

The etiology of AMD is not fully understood, which could be related to multiple factors, including genetics, chronic photodestruction effect, and nutritional disorder. AMD is classified into Dry AMD and Wet AMD. Dry AMD (also called nonexudative AMD) is not neovascular. It is characterized by progressive atrophy of retinal pigment epithelium (RPE). In the late stage, drusen and the large area of atrophy could be observed under ophthalmoscopy. Wet AMD (also called neovascular or exudative AMD), is characterized by active neovascularization under RPE, subsequently causing exudation, hemorrhage, and scarring, and will eventually cause irreversible damage to the photoreceptors and rapid vision loss if left untreated.

An early diagnosis of AMD is crucial to treatment and prognosis. Fundus photo is one of the basic examinations. The current dataset is composed of AMD and non-AMD (myopia, normal control, etc.) photos. Typical signs of AMD that can be found in these photos include drusen, exudation, hemorrhage, etc.

The ADAM challenge has 4 tasks:

Task 1: Classification of AMD and non-AMD fundus images.

Task 2: Detection and segmentation of optic disc.

Task 3: Localization of fovea.

Task 4: Detection and Segmentation of lesions from fundus images.

The Arrestee Drug Abuse Monitoring (ADAM) Program, the successor to the Drug Use Forecasting (DUF) Program (DRUG USE FORECASTING IN 24 CITIES IN THE UNITED STATES, 1987-1997 [ICPSR 9477]), measures levels of and trends in drug use among persons arrested and booked in 35 sites across the United States. The data address the following topics: (1) types of drugs used by arrestees (based on self-reports and urinalysis), (2) self-reported dependency on drugs, (3) self-reported need for alcohol/drug treatment, (4) the relationship between drug use and certain types of offenses, and (5) the relationship between self-reported indicators of drug use and indicators of drug use based on urinalysis. Participation in the project is voluntary, and all information collected from the arrestees is anonymous and confidential. The data include the arrestee's age, race, gender, educational attainment, marital status, and the charge at the time of booking. The modified ADAM/DUF interview instrument (used for part of the 1995 data and all of the 1996, 1997, 1998, and 1999 data) also collected information about the arrestee's use of 15 drugs, including recent and past use (e.g., 3-day and 30-day drug use), age at first use, and whether the arrestee had ever been dependent on drugs. As part of the ADAM program, arrestees were asked to provide a urine specimen, which was screened for the presence of ten drugs, including marijuana, opiates, cocaine, PCP, methadone, benzodiazepines (Valium), methaqualone, propoxyphene (Darvon), barbiturates, and amphetamines (positive test results for amphetamines were confirmed by gas chromatography).

Barriers and solutions to clinical trial diversity.

Database of authoritative health information about diseases, conditions, and wellness issues that offers reliable, up-to-date health information for free. It contains the latest treatments, information on drugs and supplements, the meanings of words, and medical videos and illustrations. Links to the latest topic or disease specific medical research or clinical trials are also offered. * MedlinePlus pages contain carefully selected links to Web resources with health information on over 900 topics. ** The MedlinePlus health topic pages include links to current news on the topic and related information. You can also find preformulated searches of the MEDLINE/PubMed database, which allow you to find references to latest health professional articles on your topic. * The A.D.A.M. medical encyclopedia brings health consumers an extensive library of medical images and videos, as well as over 4,000 articles about diseases, tests, symptoms, injuries, and surgeries. * The Merriam-Webster medical dictionary allows you to look up definitions and spellings of medical words. * Drug and supplement information is available from the American Society of Health-System Pharmacists (ASHP) via AHFS Consumer Medication Information, and Natural Medicines Comprehensive Database Consumer Version. ** AHFS Consumer Medication Information provides extensive information about more than 1,000 brand name and generic prescription and over-the-counter drugs, including side effects, precautions and storage for each drug. ** Natural Medicines Comprehensive Database Consumer Version is an evidence-based collection of information on alternative treatments. MedlinePlus has 100 monographs on herbs and supplements. * Interactive tutorials from the Patient Education Institute explain over 165 procedures and conditions in easy-to-read language. An XML File for the MedlinePlus Health Topics is available, http://www.nlm.nih.gov/medlineplus/xmldescription.html. The ontology is available through Bioportal, http://bioportal.bioontology.org/ontologies/MEDLINEPLUS

This study examined trends in the use of five widely abused drugs among arrestees at 10 geographically diverse locations from 2000 to 2010: Atlanta, Charlotte, Chicago, Denver, Indianapolis, Manhattan, Minneapolis, Portland Oregon, Sacramento, and Washington DC. The data came from the Arrestee Drug Abuse Monitoring Program reintroduced in 2007 (ADAM II) and its predecessor the ADAM program. ADAM data included urinalysis results that provided an objective measure of recent drug use, provided location specific estimates over time, and provided sample weights that yielded unbiased estimates for each location. The ADAM data were analyzed according to a drug epidemics framework, which has been previously employed to understand the decline of the crack epidemic, the growth of marijuana use in the 1990s, and the persistence of heroin use. Similar to other diffusion of innovation processes, drug epidemics tend to follow a natural course passing through four distinct phases: incubation, expansion, plateau, and decline. The study also searched for changes in drug markets over the course of a drug epidemic.

Myotonic dystrophy type 1 (DM1) is a rare genetic disorder, characterised by muscular dystrophy, myotonia, and other symptoms. DM1 is caused by the expansion of a CTG repeat in the 3’-untranslated region of DMPK. Longer CTG expansions are associated with greater symptom severity and earlier age at onset. The primary mechanism of pathogenesis is thought to be mediated by a gain of function of the CUG-containing RNA, that leads to trans-dysregulation of RNA metabolism of many other genes. Specifically, the alternative splicing (AS) and alternative polyadenylation (APA) of many genes is known to be disrupted. In the context of clinical trials of emerging DM1 treatments, it is important to be able to objectively quantify treatment efficacy at the level of molecular biomarkers. We show how previously described candidate mRNA biomarkers can be used to model an effective reduction in CTG length, using modern high-dimensional statistics (machine learning), and a blood and muscle mRNA microarray dataset. We show how this model could be used to detect treatment effects in the context of a clinical trial.

Study 4: Getting inside the expert’s head: An analysis of physician cognitive processes during trauma resuscitations. Crisis resource management skills are integral to leading the resuscitation of a critically ill patient. Despite their importance, crisis resource management skills (and their associated cognitive processes) have traditionally been difficult to study in the real world. The objective of this study was to derive key cognitive processes underpinning expert performance in resuscitation medicine, using a new eye-tracking–based video capture method during clinical cases. During an 18-month period, a sample of 10 trauma resuscitations led by 4 expert trauma team leaders was analyzed. The physician team leaders were outfitted with mobile eye-tracking glasses for each case. After each resuscitation, participants were debriefed with a modified cognitive task analysis, based on a cued-recall protocol, augmented by viewing their own first-person perspective eye-tracking video from the clinical encounter.

Barriers and solutions in the conference and current literature.

Beginning in 1996, the National Institute of Justice (NIJ) initiated a major redesign of its multisite drug-monitoring program, the Drug Use Forecasting (DUF) system (DRUG USE FORECASTING IN 24 CITIES IN THE UNITED STATES, 1987-1997 [ICPSR 9477]). The program was retitled Arrestee Drug Abuse Monitoring (ADAM) (see ARRESTEE DRUG ABUSE MONITORING (ADAM) PROGRAM IN THE UNITED STATES, 1998 [ICPSR 2628] and 1999 [ICPSR 2994]). ADAM extended DUF in the number of sites and improved the quality and generalizability of the data. The redesign was fully implemented in all sites beginning in the first quarter of 2000. The ADAM program implemented a new and expanded adult instrument in the first quarter of 2000, which was used for both the male (Part 1) and female (Part 2) data. The juvenile data for 2000 (Part 3) used the juvenile instrument from previous years. The ADAM program also moved to probability-based sampling for the adult male population during 2000. Therefore, the 2000 adult male sample includes weights, generated through post-sampling stratification of the data. The shift to sampling of the adult male population in 2000 required that all 35 sites move to a common catchment area, the county. The core instrument for the adult cases was supplemented by a facesheet, which was used to collect demographic and charge information from official records. Core instruments were used to collect self-report information from the respondent. Both the adult and juvenile instruments were administered to persons arrested and booked on local or state charges relevant to the jurisdiction (i.e., not federal or out-of-county charges) within the past 48 hours. At the completion of the interview the arrestee was asked to voluntarily provide a urine specimen. An external lab used the Enzyme Multiplied Immunoassay Testing (EMIT) protocols to test for the presence of ten drugs or metabolites of the drug in the urine sample. All amphetamine positives were confirmed by gas chromatography/mass spectrometry (GC/MS) to determine whether methamphetamine was used. For the adult data, variables from the facesheet include arrest precinct, ZIP code of arrest location, ZIP code of respondent's address, respondent's gender and race, three most serious arrest charges, sample source (stock, flow, other), interview status (including reason the individual selected in the sample was not interviewed), language of instrument used, and the number of hours since arrest. Demographic information from the core instrument includes respondent's age, ethnicity, residency, education, employment, health insurance coverage, marital status, housing, and telephone access. Variables from the calendar provide information on inpatient and outpatient substance abuse treatment, inpatient mental health treatment, arrests and incarcerations, heavy alcohol use, use of marijuana, crack/rock cocaine, powder cocaine, heroin, methamphetamine, and other drug (ever and previous 12 months), age of first use of the above six drugs and heavy alcohol use, drug dependency in the previous 12 months, characteristics of drug transactions in past 30 days, use of marijuana, crack/rock cocaine, powder cocaine, heroin, and methamphetamine in past 30 days, 7 days, and 48 hours, heavy alcohol use in past 30 days, and secondary drug use of 15 other drugs in the past 48 hours. Urine test results are provided for 11 drugs -- marijuana, cocaine, opiates, phencyclidine (PCP), benzodiazepines (Valium), propoxyphene (Darvon), methadone, methaqualone, barbiturates, amphetamines, and methamphetamine. The adult data files include several derived variables. The male data also include four sampling weights, and stratum identifications and percents. For the juvenile data, demographic variables include age, race, sex, educational attainment, employment status, and living circumstances. Data also include each juvenile arrestee's self-reported use of 15 drugs (alcohol, tobacco, marijuana, powder cocaine, crack, heroin, PCP, amphetamines, barbiturates, quaaludes, methadone, crystal methamphetamine, Valium, LSD, and inhalants). For each drug type, arrestees reported whether they had ever used the drug, age of first use, whether they had used the drug in the past 30 days and past 72 hours, number of days they used the drug in past month, whether they tried to cut down or quit using the drug, if they were successful, whethe

Definitions for types of racism [83].

A pilot outreach project of the National Intstitute of Justice's Arrestee Drug Abuse Monitoring (ADAM) program, the rural Nebraska ADAM program examined the prevalence and type of arrestee drug use in four rural Nebraska counties and compared the results to those found in Omaha, Nebraska, an established ADAM site. The data were collected in Madison (n=78), Dawson (n=50), Hall (n=53), and Scotts Bluff (n=149) counties, and Omaha, Nebraska, (n=202) in October and November of 1998. The catchment area for Omaha was the central city. The ADAM interview provided demographic and descriptive data, including race, age, marital status, source of income, screens of substance abuse and dependency, treatment history, arrest and incarceration experiences, and participation in local drug markets. At the conclusion of the interview, respondents were asked to provide a urine specimen. The current study included a supplemental questionnaire about methamphetamine use. The methamphetamine addendum included variables on why the respondent began and continued the use of methamphetamines, how often and how much methamphetamine was used, if and why the respondent had ever sought and completed treatment, source of the methamphetamine, and if the respondent had ever made or sold methamphetamine.

Objective: To compare the sensitivity of structural MRI and 18F-Fludeoxyglucose PET (18FDG-PET) to detect longitudinal changes in frontotemporal dementia (FTD). Methods: Thirty patients with behavioral-variant FTD (bvFTD), 7 with non-fluent/agrammatic variant primary progressive aphasia (nfvPPA), 16 with semantic variant PPA (svPPA) and 43 cognitively normal controls underwent 2-4 MRI and 18FDG-PET scans (total scan/visit=270) as part of the Frontotemporal Lobar Degeneration Neuroimaging Initiative study. Linear mixed-effects models were carried out voxel-wise and in regions of interest to identify areas showing decreased volume or metabolism over time in patients as compared to controls. Results: At baseline, patients with bvFTD showed bilateral temporal, dorsolateral and medial prefrontal atrophy/hypometabolism that extended with time into adjacent structures and parietal lobe. In nfvPPA, baseline atrophy/hypometabolism in supplementary motor cortex extended with time into left greater than right precentral, dorsolateral and dorsomedial prefrontal cortex. In svPPA, baseline atrophy/hypometabolism encompassed the anterior temporal and medial prefrontal cortex and longitudinal changes were found in temporal, orbitofrontal and lateral parietal cortex. Across syndromes, there was substantial overlap in the brain regions showing volume and metabolism loss. Even though the pattern of metabolic decline was more extensive, metabolic changes were also more variable and sample size estimates were similar or higher for 18FDG-PET compared to MRI. Conclusion: Our findings demonstrated the sensitivity of 18FDG-PET and structural MRI for tracking disease progression in FTD. Both modalities showed highly overlapping patterns of longitudinal change and comparable sample size estimates to detect longitudinal changes in future clinical trials.

Demographics of webinar #1 and #2 participants.

List of systematic reviews including new trials. (CSV 24 kb)

Included articles by data type and primary medical specialty.

Maximum intensity of solicited symptoms and signs during days 2–7 after receiving Plasmodium falciparum sporozoites by the bites of 3 aseptic mosquitoes.

Controlled human malaria infection (CHMI) is a powerful method for assessing the efficacy of anti-malaria vaccines and drugs targeting pre-erythrocytic and erythrocytic stages of the parasite. CHMI has heretofore required the bites of 5 Plasmodium falciparum (Pf) sporozoite (SPZ)-infected mosquitoes to reliably induce Pf malaria. We reported that CHMI using the bites of 3 PfSPZ-infected mosquitoes reared aseptically in compliance with current good manufacturing practices (cGMP) was successful in 6 participants. Here, we report results from a subsequent CHMI study using 3 PfSPZ-infected mosquitoes reared aseptically to validate the initial clinical trial. We also compare results of safety, tolerability, and transmission dynamics in participants undergoing CHMI using 3 PfSPZ-infected mosquitoes reared aseptically to published studies of CHMI using 5 mosquitoes. Nineteen adults aged 18–40 years were bitten by 3 Anopheles stephensi mosquitoes infected with the chloroquine-sensitive NF54 strain of Pf. All 19 participants developed malaria (100%); 12 of 19 (63%) on Day 11. The mean pre-patent period was 258.3 hours (range 210.5–333.8). The geometric mean parasitemia at first diagnosis by microscopy was 9.5 parasites/µL (range 2–44). Quantitative polymerase chain reaction (qPCR) detected parasites an average of 79.8 hours (range 43.8–116.7) before microscopy. The mosquitoes had a geometric mean of 37,894 PfSPZ/mosquito (range 3,500–152,200). Exposure to the bites of 3 aseptically-raised, PfSPZ-infected mosquitoes is a safe, effective procedure for CHMI in malaria-naïve adults. The aseptic model should be considered as a new standard for CHMI trials in non-endemic areas. Microscopy is the gold standard used for the diagnosis of Pf malaria after CHMI, but qPCR identifies parasites earlier. If qPCR continues to be shown to be highly specific, and can be made to be practical, rapid, and standardized, it should be considered as an alternative for diagnosis.Trial RegistrationClinicalTrials.gov NCT00744133 NCT00744133

Recent proposals have suggested the potential for neural biomarkers to improve clinical trial processes in neurodevelopmental conditions; however, few efforts have identified whether chronological age-based adjustments will be necessary (as used in standardized behavioral assessments). Event-related potentials (ERPs) demonstrate early differences in the processing of faces vs. objects in the visual processing system by 4 years of age and age-based improvement (decreases in latency) through adolescence. Additionally, face processing has been proposed to be related to social skills as well as autistic social-communication traits. While previous reports suggest delayed latency in individuals with autism spectrum disorder (ASD), extensive individual and age based heterogeneity exists. In this report, we utilize a sample of 252 children with ASD and 118 children with typical development (TD), to assess the N170 and P100 ERP component latencies (N170L and P100L, respectively), to upright faces, the face specificity effect (difference between face and object processing), and the inversion effect (difference between face upright and inverted processing) in relation to age. First, linear mixed models (LMMs) were fitted with fixed effect of age at testing and random effect of participant, using all available data points to characterize general age-based development in the TD and ASD groups. Second, LMM models using only the TD group were used to calculate age-based residuals in both groups. The purpose of residualization was to assess how much variation in ASD participants could be accounted for by chronological age-related changes. Our data demonstrate that the N170L and P100L responses to upright faces appeared to follow a roughly linear relationship with age. In the ASD group, the distribution of the age-adjusted residual values suggest that ASD participants were more likely to demonstrate slower latencies than would be expected for a TD child of the same age, similar to what has been identified using unadjusted values. Lastly, using age-adjusted values for stratification, we found that children who demonstrated slowed age-adjusted N170L had lower verbal and non-verbal IQ and worse face memory. These data suggest that age must be considered in assessing the N170L and P100L response to upright faces as well, and these adjusted values may be used to stratify children within the autism spectrum.

ND = not determined.